Hepatocellular Carcinoma

Cyclooxygenase-2 Associated with Shorter Disease-Free Survival

Published in Hepatitis Weekly, February 14th, 2000

Cyclooxygenase-2 (COX-2) is of limited value in predicting disease-free survival in patients who have had hepatocellular carcinoma (HCC), according to a study reported in Clinical Cancer Research.

The study, designed by researchers at Osaka University's School of Medicine, demonstrated a correlation between COX-2 expression in non-tumor tissue and shorter disease-free survival in HCC patients ("Increased expression of COX-2 in non-tumor liver tissue is associated with shorter disease-free survival in patients with hepatocellular carcinoma," Clinical Cancer Research, 1999;5(12):4005-4012).

Non-tumor tissue samples from 53 HCC patients...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (2000-02-14)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry